Business Standard

India's first mRNA Covid vaccine will be priced competitively, says company

Gemcovac does not require sub-zero temperatures for storage and transport, unlike two other international doses

Photo: Bloomberg
Premium

Photo: Bloomberg

Sohini Das Mumbai
India’s first mRNA Covid-19 vaccine Gemcovac-19 will be priced competitively with its global peers — Pfizer-BioNTech and Moderna’s vaccines, Gen¬nova Biophar-maceuticals said. Trials for use as a universal booster shot would also begin soon, and there are plans to conduct paediatric trials as well.

The vaccine’s unique selling point is that it does not require sub-zero temperatures like its peers to remain stable, but can be transported at 2-8 degrees Celsius. The vaccine can be rolled out in the private market with necessary government approvals, while Gen¬nova continues to work on trials for positioning Gemc¬ovac-19 as the universal booster. So

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 29 2022 | 7:48 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com